Meeting
2020 ASCO Virtual Scientific Program
Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma.
Authors
Aaron Rapoport
University of Maryland Greenebaum Comprehensive Cancer Center and School of Medicine, Baltimore, MD
Aaron Rapoport , James Edward Hoffman , Jonathan L. Kaufman , Kristin Blouch , Emily Butler , Maurice Phillip Deyoung , Benedetto Farsaci , Aisha N. Hasan , Andrew P. Holmes , Anne Huff , Amit Jain , Michael Jon Chisamore , Taiga Nishihori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03168438
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS8555)
DOI
10.1200/JCO.2020.38.15_suppl.TPS8555
Abstract #
TPS8555
Poster Bd #
455
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.
First Author: Jiayong Liu
Poster
2022 ASCO Annual Meeting
![ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].](https://d201v5jt9ylckg.cloudfront.net/288/14355/213211/213211_A1227_poster_pv.jpg)
ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].
First Author: Dejka M. Araujo
Poster
2017 ASCO Annual Meeting
Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).
First Author: Ben C. Creelan
Poster
2024 ASCO Annual Meeting
A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).
First Author: Naval Guastad Daver